Neutrophil-to-lymphocyte ratio (NLR) greater than 6.5 may reflect the progression of COVID-19 towards an unfavorable clinical outcome.
COVID-19
Hematological parameters
Neutrophil-to-lymphocyte ratio
Prognosis
SARS-CoV-2
Journal
Iranian journal of microbiology
ISSN: 2008-3289
Titre abrégé: Iran J Microbiol
Pays: Iran
ID NLM: 101518404
Informations de publication
Date de publication:
Oct 2020
Oct 2020
Historique:
entrez:
19
2
2021
pubmed:
20
2
2021
medline:
20
2
2021
Statut:
ppublish
Résumé
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first described during a pneumonia outbreak in Wuhan, has attracted tremendous attention in a short period of time as the death toll and the number of confirmed cases is growing unceasingly. Although molecular testing is the gold standard method of SARS-CoV-2 detection, the existence of the false-negative results presents a major limitation to this method. This retrospective Double-Centre study was conducted on 1320 COVID-19 patients recruited at Taleghani and Shohadae Tajrish Hospitals in Tehran, Iran. We analyzed the leukocyte, lymphocyte and neutrophil counts of hospitalized cases both on admission and at discharge. We also evaluated the alteration of these parameters within a seven-day follow-up. Of the whole, 1077 (81.6%) neither were admitted to intensive care unit (ICU) nor experienced death, and were defined as the mild-moderate group. Of 243 severe cases, while 59 (24.3%) were admitted to ICU and cured with the intensive care services, 184 (75.7%) patients died of the disease, either with or without ICU admission. Calculation of neutrophil-to-lymphocyte ratio (NLR) revealed that the mild-moderate cases had a lower ratio at discharge. On the other hand, the ratio was significantly higher in the death group as compared to the ICU group; highlighting the fact that patients with a higher degree of neutrophilia and a greater level of lymphopenia have a poor prognosis. We suggest that NLR greater than 6.5 may reflect the progression of the disease towards an unfavorable clinical outcome, with this notion that the ratios higher than 9 may strongly result in death.
Sections du résumé
BACKGROUND AND OBJECTIVES
OBJECTIVE
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which was first described during a pneumonia outbreak in Wuhan, has attracted tremendous attention in a short period of time as the death toll and the number of confirmed cases is growing unceasingly. Although molecular testing is the gold standard method of SARS-CoV-2 detection, the existence of the false-negative results presents a major limitation to this method.
MATERIALS AND METHODS
METHODS
This retrospective Double-Centre study was conducted on 1320 COVID-19 patients recruited at Taleghani and Shohadae Tajrish Hospitals in Tehran, Iran. We analyzed the leukocyte, lymphocyte and neutrophil counts of hospitalized cases both on admission and at discharge. We also evaluated the alteration of these parameters within a seven-day follow-up.
RESULTS
RESULTS
Of the whole, 1077 (81.6%) neither were admitted to intensive care unit (ICU) nor experienced death, and were defined as the mild-moderate group. Of 243 severe cases, while 59 (24.3%) were admitted to ICU and cured with the intensive care services, 184 (75.7%) patients died of the disease, either with or without ICU admission. Calculation of neutrophil-to-lymphocyte ratio (NLR) revealed that the mild-moderate cases had a lower ratio at discharge. On the other hand, the ratio was significantly higher in the death group as compared to the ICU group; highlighting the fact that patients with a higher degree of neutrophilia and a greater level of lymphopenia have a poor prognosis.
CONCLUSION
CONCLUSIONS
We suggest that NLR greater than 6.5 may reflect the progression of the disease towards an unfavorable clinical outcome, with this notion that the ratios higher than 9 may strongly result in death.
Identifiants
pubmed: 33604003
doi: 10.18502/ijm.v12i5.4609
pii: IJM-12-466
pmc: PMC7867698
doi:
Types de publication
Journal Article
Langues
eng
Pagination
466-474Informations de copyright
Copyright© 2020 The Authors.
Références
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Semin Thromb Hemost. 2020 Apr;46(3):379-382
pubmed: 32279286
J Infect. 2020 Jul;81(1):e6-e12
pubmed: 32283162
Swiss Med Wkly. 2020 Apr 11;150:w20247
pubmed: 32277760
Lancet Infect Dis. 2020 Jul;20(7):773
pubmed: 32171390
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
Clin Chim Acta. 2020 Nov;510:475-482
pubmed: 32798514
Am J Hematol. 2020 Jun;95(6):E131-E134
pubmed: 32129508
Clin Chem Lab Med. 2020 Jun 25;58(7):1021-1028
pubmed: 32286245
Int J Lab Hematol. 2020 Jun;42 Suppl 1:11-18
pubmed: 32311826
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32245835
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Chem Lab Med. 2020 Jun 25;58(7):1131-1134
pubmed: 32119647
J Med Virol. 2020 Jun;92(6):546-547
pubmed: 32115732
N Engl J Med. 2020 May 28;382(22):2158-2160
pubmed: 32329972
Am J Hematol. 2020 Jul;95(7):834-847
pubmed: 32282949
Radiology. 2020 Aug;296(2):E41-E45
pubmed: 32049601
Clin Chem Lab Med. 2020 Jun 25;58(7):1095-1099
pubmed: 32301746